Results indicated that some PFTs may have some prognostic utility , i.e. a trend for more clinical events to be associated with groups classified as ' aspirin resistant ' .
Study -level effect sizes were generally small and absolute outcome risk was not substantially different between ' aspirin resistant ' and ' aspirin sensitive ' design ations .
Based on assumptions of PFTs being able to accurately identify patients at high risk of clinical events and such patients benefiting from treatment modification , the economic model found that a test-treat strategy was likely to be cost-effective .
However , neither assumption is currently evidence based .
BACKGROUND The use of aspirin is well established for secondary prevention of cardiovascular disease .
However , a proportion of patients suffer repeat cardiovascular events despite being prescribed aspirin treatment .
It is uncertain whether or not this is due to an inherent inability of aspirin to sufficiently modify platelet activity .
This report aims to investigate whether or not insufficient platelet function inhibition by aspirin ( ' aspirin resistance ' ) , as defined using platelet function tests ( PFTs ) , is linked to the occurrence of adverse clinical outcomes , and further , whether or not patients at risk of future adverse clinical events can be identified through PFTs .
OBJECTIVES To review systematic ally the clinical effectiveness and cost-effectiveness evidence regarding the association between PFT design ation of ' aspirin resistance ' and the risk of adverse clinical outcome ( s ) in patients prescribed aspirin therapy .
To undertake exploratory model-based cost-effectiveness analysis on the use of PFTs .
Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers.
This study determined if meloxicam , a selective cyclooxygenase (COX)-2 inhibitor , interferes with the antiplatelet effect of aspirin using platelet aggregation and thromboxane ( Tx ) B(2 ) endpoints in healthy volunteers . Eight male and 8 female volunteers participated in this open-label , r and omized , two-treatment , two-way crossover trial . Treatment 1 was meloxicam ( 15 mg qd ) over 4 days , and then aspirin ( 100 mg qd ) was ingested 2 hours after meloxicam for an additional 7 days . Blood sample s were taken 2 , 6 , and 24 hours after the last dose . Treatment 2 consisted of only aspirin ( 100 mg ) over 2 days . Sample s were taken at the same time points . Each subject received both treatments with a 2-week washout between the treatment periods . Treatments were safe and well tolerated . The initial 4-day treatment with meloxicam had no effect on platelet aggregation but reduced serum TxB(2 ) by 64 % + /- 19 % . Addition of aspirin ( 100 mg qd ) for 7 days result ed in complete inhibition of aggregation and TxB(2 ) for 24 hours . Two-day treatment with only 100 mg aspirin also result ed in complete inhibition of platelet aggregation and TxB(2 ) . These results indicate that meloxicam does not affect the ability of aspirin to inhibit COX-1 in platelets , thereby allowing aspirin to effectively prevent platelet aggregation and reduce TxB(2 ) levels , and that meloxicam is selective for COX-2
Results indicated that some PFTs may have some prognostic utility , i.e. a trend for more clinical events to be associated with groups classified as ' aspirin resistant ' .
Study -level effect sizes were generally small and absolute outcome risk was not substantially different between ' aspirin resistant ' and ' aspirin sensitive ' design ations .
Based on assumptions of PFTs being able to accurately identify patients at high risk of clinical events and such patients benefiting from treatment modification , the economic model found that a test-treat strategy was likely to be cost-effective .
However , neither assumption is currently evidence based .
BACKGROUND The use of aspirin is well established for secondary prevention of cardiovascular disease .
However , a proportion of patients suffer repeat cardiovascular events despite being prescribed aspirin treatment .
It is uncertain whether or not this is due to an inherent inability of aspirin to sufficiently modify platelet activity .
This report aims to investigate whether or not insufficient platelet function inhibition by aspirin ( ' aspirin resistance ' ) , as defined using platelet function tests ( PFTs ) , is linked to the occurrence of adverse clinical outcomes , and further , whether or not patients at risk of future adverse clinical events can be identified through PFTs .
OBJECTIVES To review systematic ally the clinical effectiveness and cost-effectiveness evidence regarding the association between PFT design ation of ' aspirin resistance ' and the risk of adverse clinical outcome ( s ) in patients prescribed aspirin therapy .
To undertake exploratory model-based cost-effectiveness analysis on the use of PFTs .